VERITAS: Harnessing the power of nomenclature in biologic discovery
We are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision. Therefore, considering even a dozen such formats, in combinatio...
Saved in:
| Main Authors: | Riti Biswas, Ed Belouski, Kevin Graham, Michelle Hortter, Marissa Mock, Christine E. Tinberg, Alan J. Russell |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2207232 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
by: Maria U. Johansson, et al.
Published: (2023-12-01) -
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
by: Thomas Müller, et al.
Published: (2023-12-01) -
Russian-language adaptation of the international nomenclature of International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP)
by: O. Yu. Tkachenko, et al.
Published: (2021-01-01) -
Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01) -
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets
by: Soma S.R. Banik, et al.
Published: (2023-12-01)